Severe cutaneous reaction to cetuximab with possible association with the use of over-the-counter skin care products in a patient with oropharyngeal cancer

Cutaneous and Ocular Toxicology

Volumn 28, Issue 1, 2009, Pages 41-44

  Waris, Waris ^a   Naik, Seeta ^a   Idrees, Imran ^a   Taha, Hesham ^a   Camosino, Linda ^a   Mehrishi, Anshu ^a   Saif, Muhammad Wasif ^b  

^a Nassau County Community College   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cetuximab (Erbitux); Colorectal cancer (CRC); Epidermal growth factor receptor (EGFR); Erlotinib (Tarceva); Gefitinib (Iressa); Panitumumab (Vectibix); Rash

Indexed keywords

ANTI ACNE AGENT; CETUXIMAB; DIPHENHYDRAMINE; DOXYCYCLINE; HYDROCORTISONE; LANOLIN ALCOHOL; NON PRESCRIPTION DRUG; PETROLATUM; ANTINEOPLASTIC AGENT; COSMETIC; MONOCLONAL ANTIBODY;

ACNE; ADULT; ARTICLE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; DRUG WITHDRAWAL; FACE RASH; HUMAN; MACULOPAPULAR RASH; MALE; MULTIPLE CYCLE TREATMENT; NECK RASH; OROPHARYNX CARCINOMA; RASH; SELF MEDICATION; SKIN EXFOLIATION; CHEMICALLY INDUCED DISORDER; DRUG ERUPTION; MIDDLE AGED; OROPHARYNX TUMOR;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; COSMETICS; DRUG ERUPTIONS; EXANTHEMA; HUMANS; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; OROPHARYNGEAL NEOPLASMS;

EID: 70350518535     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.1080/15569520802646552     Document Type: Article

References (22)

1. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK and Ang KK. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354:567-578.
2. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005; 23:5235-5246.
3. Lacouture ME. Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 2006; 6:803-812.
4. Jacot W, Bessis D, Jorda E, Ychou M, Fabbro M, Pujol JL, Guillot B. Acneiform eruption induced by epidermal growth factor receptor inhibitors in patients with solid tumours. Br J Dermatol 2004; 151:238-241.
5. Lacouture ME, Basti S, Patel J, Benson A. fie SERIES clinic: an interdisciplinary approach to the management of toxicities to EGFR inhibitors. J Support Oncol 2006; 4:236-238.
6. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-2799.
7. Gibson TB, Ranganatha A, Grothey A. Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 2006; 6:29-31.
8. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, LoRusso P, Rishcin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110-124.
9. Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16:1425-1433.
10. Sergi C, Kahl P, Otto HF. Immunohistochemical localization of transforming growth factor-α and epithelial growth factor receptor in human fetal developing skin, psoriasis and restrictive dermopathy. Pathol Oncol Res 2000; 6:250-255.
11. Pascual JC, Belinchon I, Sivera F, Yuste A. Severe cutaneous toxicity following treatment with gefitinib (ZD1839). Br J Dermatol 2005; 153:1222-1223.
12. Peus D, Hamacher L, Pittelkow MR. EGF-receptor tyrosine kinase inhibition induces keratinocyte growth arrest and terminal diffirentiation. J Invest Dermatol 1997; 109:751-756.
13. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelson DP, Saltz LB. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810.
14. Lièvre A, Bachet J-B, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, André T, Bibeau F, Diebold M-D, Rougier P, Ducreux M, Tomasic G, Emile J-F, Penault-Llorca F, Laurent-Puig P. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26(3):374-379.
15. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effcts in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001; 144:1169-1176.
16. Saltz L, Rubin MS, Hochster H, Tchekmeydian NS. Acne-like rash predicts response in patients treated with cetuximab (IMC-C225) plus irinotecan (CPT-11) in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR) [abstract 559]. Clin Cancer Res 2001; 7:3766s.
17. Fernandez-Galar M, Espana A, Lopez-Picazo JM. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor. Clin Exp Dermatol 2004; 29:138-140.
18. Lenz HJ. Anti-EGFR mechanism of action: antitumor effect and underlying cause of adverse events. Oncology 2006; 20:5-13.
19. Albanell J, Rojo F, Averbuch S, Feyereislova A, Mascaro JM, Herbst R, Lo Russo P, Rischin D, Sauleda S, Gee J, Nicholson RI, Baselga J. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J Clin Oncol 2002; 20:110.
20. Lenz HJ, Mayer RJ, Gold PJ. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin [abstract 3510]. J Clin Oncol 2004; 22:247s.
21. Verhagen AR. Pomade acne in black skin [letter]. Arch Dermatol 1974; 110(3):465.
22. Laude TA. Approach to dermatologic disorders in black children. Semin Dermatol 1995; 14(1):15-20.